Julie Lorent

1.7k citations
16 papers · 1.0k · 1 hit paper · h-index 13

Impact in

  • Oncology top 10%
    • Cancer Immunotherapy and Biomarkers
  • Surgery top 5%
    • Bladder and Urothelial Cancer Treatments
    • Urinary and Genital Oncology Studies

Papers in

    • RNA Research and Splicing 2
    • RNA and protein synthesis mechanisms 2
    • RNA modifications and cancer 2

Julie Lorent

16 papers receiving 994 citations

Julie Lorent's Hit Papers

Randomized Phase II/III Trial Assessing Gemcitabine/Carboplatin and Methotrexate/Carboplatin/Vinblastine in Patients With Advanced Urothelial Cancer Who Are Unfit for Cisplatin-Based Chemotherapy: EORTC Study 30986 2011 · 536 citations
5360+5+10Years since publication100200300400500

Peers

Julie Lorent
Comparison fields: 5 of 88
  • Oncology 309
  • Surgery 488
  • Immunology 177
  • Cancer Research 78
  • Urology 19
Replace Jonatan Enk with:
Jonatan Enk Israel
Katherine Cook United Kingdom
Bruno Sangiorgi Brazil
Dobrin Draganov United States
Tiffany Tate United States
Katia Mayol France
Chiara Rancan United States
Clara Lubeseder–Martellato Germany
Friederike Herbst Germany
Yayi Gao China
Julie Lorent relative to Jonatan Enk Israel Jonatan Enk's profile →
Citations per field
00.5×3.4×
Jonatan Enk · 1×
Citations per year

Countries citing papers authored by Julie Lorent

Since Specialization
Citations

This map shows the geographic impact of Julie Lorent's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Julie Lorent with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Julie Lorent more than expected).

Fields of papers citing papers by Julie Lorent

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Julie Lorent. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Julie Lorent. The network helps show where Julie Lorent may publish in the future.

Co-authors

The 25 scholars most cited alongside Julie Lorent, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Julie Lorent Line = papers co-authored together Julie Lorent links everyone, so they are left out of the graph.

All Works

16 of 16 papers shown
#Work
1
Randomized Phase II/III Trial Assessing Gemcitabine/Carboplatin and Methotrexate/Carboplatin/Vinblastine in Patients With Advanced Urothelial Cancer Who Are Unfit for Cisplatin-Based Chemotherapy: EORTC Study 30986
Hit paper breakdown →
2011536
2 2016123
3 201953
4 201748
5 201542
6 201837
7 201129
8 201422
9 201822
10 201821
11 202021
12 201718
13 201516
14 200911
15 20236
16 20241

About Julie Lorent

Julie Lorent is a scholar working on Molecular Biology, Oncology, Cancer Research, Immunology and Epidemiology, having authored 16 papers that have together received 1.0k indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (3 papers), Cancer Genomics and Diagnostics (2 papers), RNA Research and Splicing (2 papers), RNA and protein synthesis mechanisms (2 papers), RNA modifications and cancer (2 papers), Trypanosoma species research and implications (1 paper), Dermatologic Treatments and Research (1 paper) and Mathematical Biology Tumor Growth (1 paper). The work is most often cited by research in Oncology (309 citations), Surgery (488 citations), Immunology (177 citations), Cancer Research (78 citations) and Urology (19 citations). Julie Lorent has collaborated with scholars based in Sweden, Canada and United States. Frequent co-authors include Maria De Santis, Graham M. Mead, Iwona Skoneczna, Sandra Collette, Pablo Maroto, Richard Sylvester, Gedske Daugaard, Joaquim Bellmunt, Michael Leahy and Ronald de Wit. Their work appears in journals such as Nucleic Acids Research, Journal of Clinical Oncology, Statistical Applications in Genetics and Molecular Biology, Blood and Biochimica et Biophysica Acta (BBA) - Reviews on Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact